Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Overview
- Phase
- Phase 4
- Intervention
- alpha-lipoic acid
- Conditions
- Type 2 Diabetes
- Sponsor
- Wuhan General Hospital of Guangzhou Military Command
- Enrollment
- 66
- Locations
- 1
- Primary Endpoint
- Alpha-lipoic acid regress the left ventricular mass
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD). Most of the attention in treating CAD in type 2 diabetes is understandably directed toward treating coronary artery conditions. However there are other treatable culprits in these patients.
Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even in the absence of hypertension. It is a strong predictor of cardiovascular events and all-cause mortality. Regression of LVH has been associated with an improved prognosis, independent of change in blood pressure (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with CAD might will be reduced if the investigators can find novel therapies to regress LVH.
Alpha-lipoic acid reduces oxidative stress which then regresses LVH. Alpha-lipoic acid can improve endothelial function in diabetic conditions. Hence, the main aim of this study was to assess whether alpha-lipoic acid could regress LVM in type 2 diabetic patients with CAD.
Investigators
Xiang Guang-da
Director of Endocrinol Dept.
Wuhan General Hospital of Guangzhou Military Command
Eligibility Criteria
Inclusion Criteria
- •Type 2 diabetes
- •Left ventricular hypertrophy
- •HbA1c below 7.0%
- •blood pressure \<130/80 mmHg
Exclusion Criteria
- •Patients were excluded if they were currently alpha-lipoic acid for one year, had a previous adverse reaction to alpha-lipoic acid.
- •hey were also excluded if they had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.
- •Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women.
Arms & Interventions
alpha-lipoic acid group
alpha-lipoic acid 600 mg daily for one year.
Intervention: alpha-lipoic acid
Outcomes
Primary Outcomes
Alpha-lipoic acid regress the left ventricular mass
Time Frame: one year
Alpha-lipoic acid 600 mg daily for one year.
Secondary Outcomes
- The change of endothelial dysfunction before and after alpha-lipoic acid intervention.(one year)